Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity
US11261171B1 · kind B1 · utility
2Cited by
16References
24Claims
0Family size
Assignees
Inventors
- Gianni Chessari
- Steven Howard
- Ildiko Maria Buck
- Benjamin David CONS
- Christopher Norbert Johnson
- Rhian Sara HOLVEY
- David Charles Rees
- Jeffrey David ST. DENIS
- Emiliano TAMANINI
- Bernard Thomas Golding
- Ian Robert Hardcastle
- Celine Florence Cano
- Duncan Charles Miller
- Martin Edward Mäntylä Noble
- Roger John Griffin
- James Daniel OSBORNE
- Joanne Peach
- Arwel Lewis
- Kim Louise Hirst
- Benjamin Paul Whittaker
- David Wyn Watson
- Dale Robert Mitchell
Key dates
| Filing date | Nov 12, 2019 |
| Grant date | Mar 1, 2022 |
| Priority date | — |
| Expiry date | Nov 12, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/05
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides a compound of formula (I): or tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the various substituents are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.